FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics, namely to gastroenterology. Disclosed is the use of trimebutine maleate in a daily dose of 600 mg to achieve maximum change in the level of pro-inflammatory cytokines IL-1, IL-6, TNF-alpha, Nf-kb and anti-inflammatory cytokine IL-10 in the gastrointestinal tract.
EFFECT: invention can be used for prevention or treatment of inflammatory diseases of gastrointestinal tract.
4 cl, 2 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION FOR TREATING FUNCTIONAL GASTROINTESTINAL DISEASES | 2019 |
|
RU2733719C1 |
| METHOD OF CORRECTING ENDOTHELIAL DYSFUNCTION WITH AZITHROMYCIN IN MODELING OF CHRONIC GRAM-POSITIVE SEPSIS | 2009 |
|
RU2400826C1 |
| METHOD OF TREATING OR PREVENTING SYSTEMIC INFLAMMATION | 2008 |
|
RU2468808C2 |
| USE OF MELATONIN FOR TREATING AND/OR PREVENTING MUCOSITIS | 2012 |
|
RU2600446C2 |
| METHOD OF USING COMPOSITION CONTAINING ACTIVE SUBSTANCE ENISAMIUM IODIDE | 2023 |
|
RU2827810C1 |
| BABY FOOD CONTAINING INACTIVATED POWDER | 2008 |
|
RU2468807C2 |
| AGENT FOR FUNCTIONAL ENTERAL DIETARY NUTRITION CONTAINING MUROPEPTIDE POSTBIOTIC, WHICH IS ABSOLUTELY SPECIFIC AGONIST TO NOD2 RECEPTORS | 2024 |
|
RU2831448C1 |
| AGENT FOR FUNCTIONAL ENTERAL DIETARY NUTRITION CONTAINING MUROPEPTIDE POSTBIOTIC, WHICH IS ABSOLUTELY SPECIFIC AGONIST TO NOD2 RECEPTORS | 2024 |
|
RU2831610C1 |
| Saccharomyces cerevisiae YEAST USED AS PROBIOTIC AND COMPOSITION BASED THEREON | 2008 |
|
RU2490324C2 |
| NEW MULTITARGET PREPARATION FOR TREATING DISEASES IN MAMMALS | 2017 |
|
RU2690188C2 |
